Abstract:BACKGROUND: Bioartificial liver support systems are becoming an effective therapy for hepatic failure. Bioreactors, as key devices in these systems, can provide a favorable growth and metabolic environment, mass exchange, and immunological isolation as a platform. Currently, stagnancy in bioreactor research is the main factor restricting the development of bioartificial liver support systems. DATA SOURCES: A PubMed database search of English-language literature was performed to identify relevant articles using the keywords "bioreactor", "bioartificial liver", "hepatocyte", and "liver failure". More than 40 articles related to the bioreactors of bioartificial livers were reviewed. RESULTS: Some progress has been made in the improvement of structures, functions, and modified macromolecular materials related to bioreactors in recent years. The current data on the improvement of bioreactor configurations for bioartificial livers or on the potential of the use of certain scaffold materials in bioreactors, combined with the clinical efficacy and safety evaluation of cultured hepatocytes in vitro, indicate that the AMC (Academic Medical Center) BAL bioreactor and MELS (modular extracorporeal liver support) BAL bioreactor system can partly replace the synthetic and metabolic functions of the liver in phase I clinical studies. In addition, it has been indicated that the microfluidic PDMS (polydimethylsiloxane) bioreactor, or SlideBioreactor, and the microfabricated grooved bioreactor are appropriate for hepatocyte culture, which is also promising for bioartificial livers. Similarly, modified scaffolds can promote the adhesion, growth, and function of hepatocytes, and provide reliable materials for bioreactors. CONCLUSIONS: Bioreactors, as key devices in bioartificial livers, play an important role in the therapy for liver failure both now and in the future. Bioreactor configurations are indispensable for the development of bioartificial livers used for liver failure, just as the modified scaffold materials available for bioreactors are favorable to the construction of effective bioartificial livers.

Albumin Dialysis in Artificial Liver Support Systems: Open-Loop or Closed-Loop Dialysis Mode?

The Comparison of Albumin Dialysis between Open- and Closed-Loop Dialysis Modes

Numerical Simulation and Experimental Validation of Bound Solute Dialysis in Artificial Liver Support Systems

Predicting the Impact of Dialyzer Choice and Binder Dialysate Flow Rate on Bilirubin Removal

Similarities, Differences, and Potential Synergies in the Mechanism of Action of Albumin Dialysis Using the MARS Albumin Dialysis Device and the CytoSorb Hemoperfusion Device in the Treatment of Liver Failure

Development of Liposome As a Novel Adsorbent for Artificial Liver Support System in Liver Failure.

Efficient removal of serum ilirubin by a novel artificial liver support system using albumin convection: A pilot study

[Current Status and Perspectives of Artificial Liver for Treatment of Acute-on-chronic Liver Failure].

Efficient removal of serum bilirubin by a novel artificial liver support system using albumin convection: a pilot study

Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts

Preliminary Examination on Removal of Protein-Bound Toxins by Hemolipodialysis

Evaluation of Hydromechanical and Functional Properties of Diversion-Type Microcapsule-Suspension Bioreactor for Bioartificial Liver

Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis

Comparison of High-Flux, Super High-Flux, Medium Cut-Off Hemodialysis and Online Hemodiafiltration on the Removal of Uremic Toxins

Progress in bioreactors of bioartificial livers.

Sorbent-based artificial liver devices: principles of operation, chemical effects and clinical results

Development of a Novel Artificial Liver Support System

Superior dialytic removal of bilirubin and bile acids by free fatty acid displacement and its combination with albumin dialysis

A Theoretical Ultrafiltration Model for Albumin-Bound Toxin Dialysis

Superior Dialytic Removal Of Bilirubin And Bile Acids By Free Fatty Acid Displacement And Its Combination With Albumin Dialysis (Jun, 10.1111/Aor.14004, 2021)

[Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain]